Evidence map›Paper›PMID 20483366›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2010

Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles.

Michael Chorny, Elizabeth Hood, Robert J Levy, Vladimir R Muzykantov

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 114 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Sex-based differences of antioxidant enzyme nanoparticle effects following traumatic brain injury.Journal of controlled release : official journal of the Controlled Release Society · 2023
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Stability of Therapeutic Enzymes: Challenges and Recent Advances.Advances in experimental medicine and biology · 2019
    Review
  11. Article
  12. Targeting therapeutics to endothelium: are we there yet?Drug delivery and translational research · 2018
    Review
  13. Article
  14. Targeting vascular (endothelial) dysfunction.British journal of pharmacology · 2017
    Review
  15. Review
  16. Flow shear stress differentially regulates endothelial uptake of nanocarriers targeted to distinct epitopes of PECAM-1.Journal of controlled release : official journal of the Controlled Release Society · 2015
    Article
  17. Review
  18. Stimuli-responsive nanomaterials for therapeutic protein delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Michael ChornyDepartment of Pediatrics, The Children's Hospital of Philadelphia, Abramson Research Bldg., Ste. 702, 3615 Civic Center Blvd., Philadelphia, PA 19104, USA. chorny@email.chop.edu
Elizabeth Hood
Robert J Levy
Vladimir R Muzykantov
Children's Hospital of Philadelphia · USTranslational Therapeutics (United States) · US

Funding

INSTITUTIONAL CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR024134 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2006 to 2011
$70.4M
Reactive oxygen species and anti-oxidants in ALIP01HL079063 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BATES, SANDRA R · 2005 to 2009
$12.1M
Gene Delivery StentsR01HL072108 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI LEVY, ROBERT J · 2003 to 2013
$3.9M
Targeting Carriers with Controlled Geometry to EndotheliumR01HL087036 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2008 to 2012
$2.0M
Augmentation of Antioxidant Defenses by ImmunotargetingR01HL073940 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI MUZYKANTOV, VLADIMIR R · 2004 to 2007
$1.6M
Gene Delivery Stents AAV FormulationsR56HL072108 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI FISHBEIN, ILIA, LEVY, ROBERT J · 2015 to 2015
$420k
NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1RR024134NHLBI NIH HHS HL 72108NHLBI NIH HHS P01 HL079063NHLBI NIH HHS R01 HL072108NHLBI NIH HHS R01 HL073940NHLBI NIH HHS R01 HL079603NHLBI NIH HHS R01 HL087036NHLBI NIH HHS R56 HL072108
6 · The paper itself

Abstract

Antioxidant enzymes have shown promise as a therapy for pathological conditions involving increased production of reactive oxygen species (ROS). However the efficiency of their use for combating oxidative stress is dependent on the ability to achieve therapeutically adequate levels of active enzymes at the site of ROS-mediated injury. Thus, the implementation of antioxidant enzyme therapy requires a strategy enabling both guided delivery to the target site and effective protection of the protein in its active form. To address these requirements we developed magnetically responsive nanoparticles (MNP) formed by precipitation of calcium oleate in the presence of magnetite-based ferrofluid (controlled aggregation/precipitation) as a carrier for magnetically guided delivery of therapeutic proteins. We hypothesized that antioxidant enzymes, catalase and superoxide dismutase (SOD), can be protected from proteolytic inactivation by encapsulation in MNP. We also hypothesized that catalase-loaded MNP applied with a high-gradient magnetic field can rescue endothelial cells from hydrogen peroxide toxicity in culture. To test these hypotheses, a family of enzyme-loaded MNP formulations were prepared and characterized with respect to their magnetic properties, enzyme entrapment yields and protection capacity. SOD- and catalase-loaded MNP were formed with average sizes ranging from 300 to 400 nm, and a protein loading efficiency of 20-33%. MNP were strongly magnetically responsive (magnetic moment at saturation of 14.3 emu/g) in the absence of magnetic remanence, and exhibited a protracted release of their cargo protein in plasma. Catalase stably associated with MNP was protected from proteolysis and retained 20% of its initial enzymatic activity after 24h of exposure to pronase. Under magnetic guidance catalase-loaded MNP were rapidly taken up by cultured endothelial cells providing increased resistance to oxidative stress (62+/-12% cells rescued from hydrogen peroxide induced cell death vs. 10+/-4% under non-magnetic conditions). We conclude that non-polymeric MNP formed using the controlled aggregation/precipitation strategy are a promising carrier for targeted antioxidant enzyme therapy, and in combination with magnetic guidance can be applied to protect endothelial cells from oxidative stress mediated damage. This protective effect of magnetically targeted MNP impregnated with antioxidant enzymes can be highly relevant for the treatment of cardiovascular disease and should be further investigated in animal models.

Indexed as

AntioxidantsCatalaseCell LineCell SurvivalDrug CarriersDrug CompoundingDrug StabilityEndothelial CellsEndothelium, VascularHumansMagnetite NanoparticlesMicroscopy, Electron, TransmissionOxidative StressParticle SizePeptide HydrolasesProtein StabilityAntioxidantsCatalaseDrug CarriersMagnetite NanoparticlesPeptide HydrolasesSuperoxide Dismutase

Identifiers

PMID20483366
PMCPMC2914110
OpenAlexW2082884007

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.